Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IL13Rα2-Specific CAR T Cells for Recurrent/Refractory Malignant Glioma
NCT02208362Phase 1Active, not recruiting
- Sponsor
- City of Hope
- Start
- Jun 2015
- Primary completion
- Feb 2021
- Modality
- Prophylactic Vaccines, CAR-T Cells, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of IL13Ra2-specific CAR T cells in malignant glioma (5 arms), sponsored by City of Hope. Primary endpoints: Number of Participants With Grade 3 or Higher Toxicity Related to CAR T Cells at 11 months and Number of Participants Experiencing a Dose Limiting Toxicity (DLT) at 4 weeks. Started Jun 2015; status: active, not recruiting.
02
Drugs
IL13Ra2-specific CAR T cells
03
Conditions
malignant glioma
Beyond the preview
Go deeper on NCT02208362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02208362.